301. 黄斑ジストロフィー Macular dystrophy Clinical trials / Disease details

臨床試験数 : 46 / 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67

diseases per page:

Showing 1 to 10 of 46 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05417126 (ClinicalTrials.gov)	July 5, 2022	9/6/2022	Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects Wi ...	A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Int ...	Stargardt Disease	Biological: Gene Therapy-vMCO-010	Nanoscope Therapeutics Inc.	NULL	Active, not recruiting	16 Years	N/A	All	6	Phase 2	United States
2	NCT05244304 (ClinicalTrials.gov)	March 28, 2022	20/1/2022	Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Diseasein Ado ...	Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and ...	Stargardt Disease 1	Drug: Tinlarebant;Drug: Placebo	Belite Bio, Inc	NULL	Recruiting	12 Years	18 Years	All	60	Phase 3	China;France;Germany;Hong Kong;Netherlands;Switzerland;Taiwan;United Kingdom;Australia;Belgium;Unite ...
3	NCT05266014 (ClinicalTrials.gov)	March 12, 2021	26/1/2022	This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability ...	Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolera ...	Stargardt Disease	Drug: tinlarebant	RBP4 Pty Ltd	Belite Bio, Inc	Active, not recruiting	12 Years	18 Years	All	13	Phase 1/Phase 2	Australia;Taiwan
4	NCT04658251 (ClinicalTrials.gov)	March 3, 2021	1/12/2020	Study of New Mutations in Cone Disorders	Functional Study of Intronic Variants in Inherited Cone Disorders	Retinal Dystrophy, Cone-Rod;Cone Dystrophy;Cone Rod Dystrophy;Macular Degeneration	Genetic: Blood and/or skin biopsy	University Hospital, Lille	NULL	Recruiting	3 Years	N/A	All	20		France
5	NCT04545736 (ClinicalTrials.gov)	November 23, 2020	10/9/2020	Oral Metformin for Treatment of ABCA4 Retinopathy	Oral Metformin for Treatment of ABCA4 Retinopathy	ABCA4 Retinopathy;Stargardt Disease;Retinal Dystrophy;Retinal Degeneration	Drug: Metformin hydrochloride	National Eye Institute (NEI)	NULL	Recruiting	12 Years	N/A	All	38	Phase 1/Phase 2	United States
6	NCT04489511 (ClinicalTrials.gov)	October 1, 2020	21/7/2020	Study of STG-001 in Subjects With Stargardt Disease	A Phase 2a Study of the Safety, Pharmacokinetics and Pharmacodynamics of STG-001 in Subjects With St ...	Stargardt Disease-1	Drug: STG-001	Stargazer Pharmaceuticals, Inc.	NULL	Completed	18 Years	55 Years	All	10	Phase 2	United States
7	NCT04239625 (ClinicalTrials.gov)	December 20, 2019	11/1/2020	Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)	A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long T ...	Stargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Sta ...	Drug: ALK-001	Alkeus Pharmaceuticals, Inc.	NULL	Enrolling by invitation	8 Years	70 Years	All	140	Phase 2	United States
8	EUCTR2018-001496-20-IT (EUCTR)	18/07/2019	17/06/2021	A phase II study of soraprazan in patients with Stargardt disease	A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate ...	Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's dise ...	Product Name: soraprazan Product Code: [EU/3/13/1208 orphan] INN or Proposed INN: (7R,8R,9R)-2.3-Dimet ...	Katairo GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	90	Phase 2	Netherlands;Germany;United Kingdom;Italy
9	EUCTR2018-003498-82-DK (EUCTR)	11/06/2019	17/12/2018	Evaluation of Emixustat for the Treatment of Stargardt Disease	A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixusta ...	Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's dise ...	Product Name: Emixustat hydrochloride Product Code: ACU-4429 INN or Proposed INN: Emixustat hydrochlorid ...	Acucela Inc.	NULL	Not Recruiting			Female: yes Male: yes	194	Phase 3	United States;France;Canada;Spain;Brazil;Denmark;South Africa;Netherlands;Germany;United Kingdom;Ita ...
10	EUCTR2018-003498-82-IT (EUCTR)	29/05/2019	13/01/2021	Evaluation of Emixustat for the Treatment of Stargardt Disease	A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixusta ...	A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixusta ...	Product Name: Emixustat hydrochloride Product Code: [ACU-4429] INN or Proposed INN: Emixustat hydrochlor ...	Acucela Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	162	Phase 3	France;United States;Canada;Spain;Brazil;Denmark;South Africa;Netherlands;Germany;United Kingdom;Ita ...

First Previous1 2 3 4 5Next Last